Introduction
Type 1 diabetes is a progressive heterogeneous autoimmune disease caused by the destruction of insulin secreting β-cells by T cells. Most patients have a period of improved glucose control soon after diagnosis. The partial remission period is the period during which patients still respond to low levels of insulin (b0.5 U/Kg body weight) to achieve euglycemia [1] [2] [3] [4] . This partial remission period, also termed the honeymoon period, is variable, lasting from several weeks to over a year [5] [6] .
Clinical studies suggest that immunotherapy is most effective if started early post-diagnosis [7] [8] [9] [10] at a time when patients generally have greater residual β-cell mass. This might be explained if therapeutic intervention prevents or slows down the ongoing destruction of the remaining β-cells, or enhances ongoing mechanisms to improve β-cell mass and inhibit autoimmunity. β-cell mass retention results in good glucose control that can in turn further reduce β-cell damage by limiting glucose toxicity. It is reasonable then to suggest that patients with a prolonged period of improved glucose control and partial remission might be particularly responsive to therapy. However, to date there is no way to predict which newly diagnosed patients will go on to have a long or short period of partial remission. This pilot study was designed to test whether the immune cell profile at diagnosis correlates with length of partial remission in newly diagnosed patients with type 1 diabetes.
The immune cell subsets measured include CD4 + naïve, memory and regulatory (Treg) cell subsets, and CD25 + CD127 hi cells. To measure partial remission both insulin dose and HbA1c are combined in a standard formula to provide a single value, the Insulin Dose Adjusted A1c (IDAA1c). The IDAA1c value reflects the quality of glucose control. An IDAA1c value equal to or b9 is given to indicate partial remission [11] . Our data show that of the cell subsets tested, the relative frequency of CD4 + hi cells do not express Foxp3, the transcription factor for Treg cells [14] [15] [16] [17] , neither do they express LAG-3 and CD49b, markers that identify Tr1 regulatory cells [23] , indicating that they are neither 
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Clinical Immunology j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y c l i m CD44 and the CD44 variant v6, signaling through which promotes expression of Foxp3, IL-2, TGF-β and IL-10 [12] [13] all critical requirements for the development and function of Treg [14] [15] [16] [17] [18] [19] [20] [21] and Tr1 [22] . These data strongly suggest that the relative frequency of CD4 + memory cell subsets that are associated with immune regulation can predict length of remission in patients with T1D, and warrant further investigation in a validation study with a large cohort of patients.
Materials and methods

Patient population
Archived peripheral blood mononuclear cells (PBMC) from 9 female and 10 male newly diagnosed type 1 diabetic patients were obtained from TrialNet Ancillary Studies. Patients were between 9 and 16 years of age and enrolled in the placebo groups of TrialNet clinical trials. Two PBMC samples from each patient were analyzed, one taken at baseline (within 3 months of diagnosis) and one 3 months later. The study was blinded. Clinical parameters were evaluated at baseline and again at 3, 6, 9, 12, 18, and 24 months post-baseline.
Healthy subject population
Whole blood from healthy donors was obtained from the Normal Blood Donor Program at The Scripps Research Institute (TSRI). Human Subjects protocols and consent forms were reviewed and approved by both TSRI IRB and San Diego Biomedical Research Institute (SDBRI) IRB. Whole blood was collected in heparin and processed within 2 h. PBMC were isolated using standard methods and either used immediately or frozen in liquid nitrogen, as indicated for each experiment.
Measurement of partial remission and β-cell function using IDAA1c and C-peptide AUC
A standard formula, HbA1c (%) + (4 × insulin dose (U/kg per 24 h), is used to take into account both insulin requirement and HbA1c levels in a single value, the Insulin Dose Adjusted A1c (IDAA1c). An IDAA1c equal to or b 9 indicates the partial remission period [11] . Partial remission measured using IDAA1c is associated with a C-peptide AUC 120 level of at least 108, equivalent to a mean C-peptide level of 0.9 ng/ml/min or 0.3 pmol/ml [11] . In this study the end of partial remission is between the last visit when IDAA1c is equal to or b 9 and the first visit when IDAA1c is N9. A more accurate estimate of time of end of partial remission was determined by interpolating between these two observed values. Length of remission is the time between diagnosis and end of remission. Stimulated C-peptide AUC was calculated over 120 min using the trapezoidal rule, with observed C-peptide values at 0, 15, 30, 60, 90, and 120 min.
Type 1 diabetes PBMC analysis by flow cytometry
Vials of PBMC from patients with T1D were thawed and stained with each of the following panels of mAbs. Healthy subject PBMC were thawed and used as positive controls for mAb staining in each experiment. To distinguish dominantly naïve (CD45RA + , CD45RO − ) and
) cells within the total CD4 compartment we used either APC-conjugated anti-CD4 (BioLegend, clone OKT4) with PerCP-Cy5-5-conjugated anti-CD3 (BioLegend, clone OKT3), PEconjugated anti-CD45RO (BioLegend, clone UCHL1), and APC-H7-conjugated anti-CD45RA (BD Biosciences, clone HI100). (Note: anti-CCR7 and anti-CD62L were not used on frozen PBMC because in our hands the relative frequency of cells expressing either CCR7 and CD62L is consistently less on frozen/thawed cells than it is on fresh cells.) To identify CD4 + CD25 + CD127 hi and Tregs (CD25 + CD127 low ) we used the BD Biosciences Treg cocktail (FITC-conjugated anti-CD4 (clone SH3), Alexa Fluor 647-conjugated anti-CD127 (clone HIL-7R-M21), and PE-Cy7-conjugated anti-CD25 (clone 2 A3)), with PerCPCy5-5-conjugated anti-CD3. Activated and resting Treg were identified using FITC-conjugated anti-CD4 (BioLegend, clone OKT4), APC-H7-conjugated anti-CD45RA (BD Biosciences, clone HI100) and PerCPCy5.5-conjugated anti-Foxp3 (BD Biosciences, clone 236a/E7). To identify Th1-type effector cells and Treg subsets thawed PBMC were washed twice in RPMI (Invitrogen) with 10% human AB serum and rested at 37°C overnight. Cells were resuspended in RMPI with 10% human AB serum, HEPES (Gibco BRL), glutamine, penicillin, streptomycin (Irvine Scientific), and 2-mercaptoethanol (Sigma-Aldrich) and cultured in 24 well plates at a concentration of 1-3 × 10 6 cell per ml with 50 ng/ml PMA (Sigma) and 1 μM Ionomycin (Sigma). hi , are associated with length of partial remission. Therefore, in the manuscript we focus our attention on these cell subsets. hi was determined by cell surface phenotype using BV510-conjugated CCR7 (BioLegend, clone GO43H7), BV421-conjugated anti-CD62L (BioLegend, clone DREG-56), PE-conjugated anti-CD28 (BioLegend, clone CD28.2), and APC-H7-conjugated anti-CD45RA. To determine the expression of CD44, CD44 variants, Foxp3, LAG-3 and CD49b on CD4 + CD25 + CD127 hi cells either BV510-conjugated anti-CD44 (BioLegend, clone IM7), or biotin-conjugated anti-CD44v4 (eBioscience, clone VFF-11), or biotin-conjugated antiCD44v6 (eBioscience, clone VFF-18), or PerCP-Cy5.5-conjugated Foxp3, or PE-conjugated anti-LAG-3 (BD Bioscience, clone T47-530), or BV421-conjugated anti-CD49b (BD Bioscience, clone 12F1) were used. Cells labeled with biotin-conjugated mAbs were incubated with BV510-conjugated streptavidin. Sample acquisition was as described for frozen PBMC samples Registry identifiers for the antibodies used for target antigens in Flow Cytometry experiments are as follows: CD45RO-PE-AB_571946; CD4-APC-AB_571946; CD4-FITC-AB571951; CD3-PerCP-Cy5.5-AB_ 2561628; CD45RA-APC-H7-AB_1727497; CD62L-BV421-AB_2562914; CCR7-BV510-AB_2563866; CD44-BV510-AB-2,561,391; CD28-PE-AB_314309; LAG-3-PE-AB_2571727; CD49b-BV421-AB_2571728; Treg cocktail-AB_1645496; T-bet-BV421-AB_10896427; TNF-α-PE-AB_466207; IL-2-PE-AB_466151; IFN-γ-PE-AB_1272026; IL-4-PE-AB_1548817; CD44v6-biotin-AB_10596818; CD44v4-biotin-AB_ 10596812, Foxp3-PerCP-Cy5.5-AB_10714077.
Statistics
Descriptive statistics are reported on the clinical variables. Associations of clinical variables with length of remission were assessed initially through Pearson correlations, as length of partial remission was available for each subject. Univariate and multivariate Cox proportional hazards regression analyses were then performed with length of remission as the outcome variable. Covariates included the various cell subset frequencies at baseline (time 0), along with baseline IDAA1c, HbA1c, Cpeptide levels and insulin dose requirement (U/kg/24 h). These results are reported as hazard ratios, with 95% confidence intervals. We performed all subsets regressions, but limited consideration to models with only two covariates, because of the relative paucity of data. All analyses were performed with Graphpad Prism and SPSS V21.0 (IBM Corporation, 2012).
Results
Changes in IDAA1c and C-peptide AUC with time
IDAA1c (see Table 1A in Ref [23] ) and C-peptide AUC (see Table 1B in Ref [23] ) were measured for each patient within 3 months of diagnosis (baseline), and then at 3, 6, 9, 12, 18 and 24 months post-baseline. In Fig.  1 we show the increase in IDAA1c reflecting a decline in glucose control (Fig. 1A) , and a decline in stimulated C-peptide release, measured as Cpeptide AUC (Fig. 1B) over the first 24 months post-diagnosis for each patient.
Immune cell subsets measured in patients newly diagnosed with T1D
Of the cell subsets tested only CD4 + CD25 + CD127 hi , CD45RO
+ memory cells and activated Treg frequencies are significantly associated with length of partial remission. Therefore, we will limit the data shown to these three cell subsets. CD4 + CD45RO + memory and CD45RA + naive cells ( Fig. 2A ), activated and resting Treg (Fig. 2B ) and CD4 + CD25 + CD127 hi and Treg (Fig. 2C) , were identified and their relative frequencies in patient PBMC at baseline and at 3 months post-baseline determined. Patients were stratified for analysis (see Table 2 in Ref [23] ) into those with good glycemic control (having a length of partial remission longer than 1 month, n = 12, Fig. 2D ) and those with poor glycemic control (having a length of partial remission shorter than 1 month, n = 7, Fig. 2E ). The correlation between frequencies of immune cell subsets measured at baseline with length of partial remission was determined in patients with good glycemic control. The length of partial remission correlates significantly with relative frequency of CD45RO + memory cells (Fig. 3A) , activated Treg (Fig. 3B) , and CD25 + CD127 hi cells ( Fig. 3C and D) . Although the outlier shown in Fig. 3C (red circle, subject X) improved the correlation between the frequency of CD25 + CD127 hi cells and length of remission, a correlation of 0.61 was achieved without it (Fig. 3D) . In contrast, the relative frequency of Tregs (data not shown), CD45RA + naive cells (data not shown), resting Treg (data not shown), baseline IDAA1c (Fig. 3E ) and C-peptide AUC (Fig. 3F) do not significantly correlate with length of remission. The relative frequency of activated Treg, but no other cell subset, also correlates with length of time HbA1c levels are maintained at or below 7% (see Figure 1 in Ref [23] ). The relative frequency of CD45RO + memory cells, and CD25 + CD127
hi cells also correlated with length of remission when measured at 3 months post-baseline (see Figure 2 in Ref [23] ). No correlation was noted between the relative frequency of any cell subsets tested and either body mass index (BMI), age at diagnosis, or insulin dose requirement at any time tested (data not shown). These data show that relative frequency of certain immune cell subsets at diagnosis does correlate with rate of disease progression after diagnosis. Regression coefficients from the three models are given in Table 1 . The regression coefficient B (or, exp(B)) is the change in the log hazard (or, hazard) for a one unit change in the corresponding covariate when markers that identify Tr1 cells [24] , was also determined. PBMC from healthy adult donors were labeled for CD3, CD4, CD25, CD127, and either Foxp3, or LAG-3 and CD49b and the expression of Foxp3 (Fig. 5A and B) and LAG-3 and CD49b ( Fig. 5C-H 
CD25 + CD127 hi cells express CD44v6 and a high density of CD44
Signaling via CD44 and the CD44v6 variant can promote expression of Foxp3, IL-2, TGF-β and IL-10 [12] [13] , factors that are critical for the development and function of Treg [14] [15] [16] [17] [18] [19] [20] [21] and Tr1 [22] . CD25 + nonTreg cells in PBMC from healthy subjects were investigated for their expression of CD44 and CD44v6 as well as CD44v4. CD44v4 is expressed on resting naïve cells and therefore we predicted that CD25 + nonTreg cells would not express CD44v4 [13] . Our data show that CD44v6 is expressed on 64.9 ± 10.9% of CD25 + non-Treg while CD44v4 is expressed on b3% (Fig. 6A and B) . Moreover, CD25 + CD127 hi cells express a significantly higher density of CD44 than do Treg cells ( Fig. 6C  and D) . These data might suggest a mechanistic link between the relative frequency of CD25 + non-Treg cells and protection from diabetes progression. (Fig. 7) .
Discussion
In this study we show a significant correlation between the relative frequency of CD4 [29] [30] . Tregs can develop in the periphery (induced or iTregs) [31] [32] as well as in the thymus (natural or nTregs) [29] and the expression of Foxp3 by Tregs is an absolute requirement for their suppressor function [14] [15] [16] [17] . There are clear differences in the Treg compartment in patients with type 1 diabetes compared to healthy subjects [33] [34] , and modulating regulatory cell number can alleviate type 1 diabetes in the NOD mouse model for type 1 diabetes [35] [36] . Although increasing Treg numbers is not always associated with protection after immunomodulation [37] , in recent clinical trials, several patients treated with ex vivo expanded polyclonal Treg had higher C-peptide levels than untreated controls supporting a role for Treg in protection from disease progression [38] [39] . Tr1 cells also have anti-inflammatory potential for therapeutic intervention in type 1 diabetes [40] . Signaling via cell surface CD25, CD127 and CD44 expressed by CD25 + CD127 hi provides alternative pathways for regulating the relative frequency of this cell population. In inflammatory environments, including in patients with type 1 diabetes, soluble CD127 and CD25 (sCD127 and sCD25) released from activated T cells act as IL-7 and IL-2 antagonists, blocking IL-7 and IL-2 mediated signaling and the expansion of CD127 + and CD25 + T cells [44] [45] [46] . This leaves CD127 + and CD25 + cells vulnerable to depletion [44] [45] [46] . However, hyperglycemia can result in glycation of sCD127 making it ineffective as an IL-7 antagonist in patients with poor glucose control [44] . On the other hand, CD44 co-stimulation induces CD25 expression promoting CD25 signaling in the presence of lower circulating levels of IL-2 [13] . In addition, CD44, and its variant CD44v6, both receptors for hyaluronan (HA), inhibit apoptosis on cross-linking CD44 [12, [47] [48] . During inflammation HA is broken down into a low m.wt form that is ineffective in crosslinking CD44 [49] . It is possible that the relative frequency of CD25 + CD127 hi reflects the level of inflammation and circulating inflammatory mediators in patients with type 1 diabetes. Previously published studies have shown immunological changes during the remission period in patients with type 1 diabetes, but whether these changes are causally related to remission remains unclear [50] . Thus, an early study showed an increase in T cell proliferative responses to insulin secretory granules in a small number of children with type 1 diabetes during the remission period [51] . Later studies reported that Foxp3 expression at diagnosis predicted poor future glycemic control [52] and that Treg suppressor function transiently decreased during the remission period while effector cytokine secretion increased [53] . The published data overall point to heightened T cell activity during remission, a condition necessary for the co-development of Tregs and peripheral tolerance as well as effector cell function [50] . Our data are consistent with a non-antigen-specific non-Treg CD4 + T cell change in the immune cell profile in patients with type 1 diabetes. This might suggest that strategies to re-establish immune homeostasis are important in the treatment of type 1 diabetes. Amongst the many susceptibility loci for autoimmune disease there are several that link CD25, the high affinity IL-2 receptor (IL-2RA), with disease risk. Susceptible IL-2RA haplotypes show reduced signaling to IL-2 in Tregs in type 1 diabetic and multiple sclerosis patients [33] as well as healthy individuals [54] . Moreover, individuals with protective bdbiosciences.com/documents/T_Cell_BD_Human_Regulatory_ Cocktail.pdf).
Conclusions
This pilot study has identified the relative frequency of CD4 progression. Whether this cell subset plays an active role in maintaining partial remission, either by enhancing regulatory T cell function, or by some other mechanism, remains to be determined. These data warrant further investigation in a validation study with a large cohort of patients.
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